# EDGAR Filing Document

**Accession Number:** 0000842023
**File Stem:** 0000914190-26-000092
**Filing Date:** 2026-5
**Character Count:** 9513
**Document Hash:** d73143b78d65b0d81893ee3f67ba57e6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-26-000092.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0000914190-26-000092

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260508

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Herr Amy E.
- **CENTRAL INDEX KEY:** 0002055523

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 26968358

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **STREET 2:** SUITE 1500
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 612-379-8854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Herr Amy E.<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-08 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 2680 | D |  |
| Common Stock | 2026-05-08 |  | M |  | 6636 | A | $47.60 | 6836 | I | By significant other |
| Common Stock | 2026-05-08 |  | S |  | 6636 | D | 48.28<sup>(1)</sup> | 200 | I | By significant other |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $72.05 |  |  |  |  |  |  | 2025-10-24 | 2035-02-03 | Common Stock | 2415 |  | 2415 | D |  |
| Stock Option (Right to Buy) | $60.96 |  |  |  |  |  |  | <sup>(2)</sup> | 2035-10-30 | Common Stock | 3777 |  | 3777 | D |  |
| Stock Option (Right to Buy) | $47.60 | 2026-05-08 |  | M |  |  | 6636 | <sup>(3)</sup> | 2026-08-07 | Common Stock | 6636 | $0 | 0 | I | By significant other |
| Stock Option (Right to Buy) | $66.97 |  |  |  |  |  |  | <sup>(3)</sup> | 2027-08-05 | Common Stock | 4472 |  | 4472 | I | By significant other |
| Stock Option (Right to Buy) | $120.46 |  |  |  |  |  |  | <sup>(3)</sup> | 2028-08-06 | Common Stock | 2076 |  | 2076 | I | By significant other |
| Stock Option (Right to Buy) | $94.52 |  |  |  |  |  |  | <sup>(4)</sup> | 2029-08-15 | Common Stock | 2104 |  | 2104 | I | By significant other |
| Stock Option (Right to Buy) | $84.61 |  |  |  |  |  |  | <sup>(5)</sup> | 2030-08-15 | Common Stock | 1084 |  | 1084 | I | By significant other |
| Stock Option (Right to Buy) | $74.91 |  |  |  |  |  |  | <sup>(6)</sup> | 2034-08-15 | Common Stock | 1468 |  | 1468 | I | By significant other |
| Stock Option (Right to Buy) | $72.05 |  |  |  |  |  |  | <sup>(7)</sup> | 2035-02-03 | Common Stock | 344 |  | 344 | I | By significant other |
| Restricted Stock Units | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(9)</sup> | <sup>(8)</sup> | Common Stock | 118 |  | 118 | I | By significant other |
| Restricted Stock Units | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(10)</sup> | <sup>(9)</sup> | Common Stock | 320 |  | 320 | I | By significant other |
| Restricted Stock Units | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(11)</sup> | <sup>(10)</sup> | Common Stock | 77 |  | 77 | I | By significant other |
| Restricted Stock Units | <sup>(8)</sup> |  |  |  |  |  |  | <sup>(12)</sup> | <sup>(11)</sup> | Common Stock | 932 |  | 932 | I | By significant other |
| Stock Option (Right to Buy) | $53.60 |  |  |  |  |  |  | <sup>(13)</sup> | 2035-08-15 | Common Stock | 2735 |  | 2735 | I | By significant other |

---

### Footnotes:

(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.19 to $48.31, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(2) This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

(3) Fully vested.

(4) Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.

(5) Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.

(6) Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

(7) Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.

(8) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(9) 118 restricted stock units vest on 8/15/2026.

(10) 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.

(11) 38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.

(12) 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.

(13) Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.

**Signature:** /s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed  
**Date:** 2026-05-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**